Introduction
Lithuania is a country in Northern Europe, the largest of the three Baltic States. It is situated along the southeastern shore of the Baltic Sea with a territory of 65 200 km 2 and a population of 3 million inhabitants. Starting in 1940, Lithuania was occupied by the Soviet Union. On March 11, 1990 , the year before the breakup of the Soviet Union, Lithuania became the first Soviet republic to declare independence. In the early period of independence (1991) (1992) (1993) hemodialysis (HD) was only acetate and available only for recipients waiting for transplantation. There were old HD machines, no water treatment, lack of nephrology literature in English and no competent training in nephrology. This was followed by tremendous progress in renal replacement therapy later on: full renovation and expansion of HD service, start of peritoneal dialysis, establishment of a second center of kidney transplantation, development of a Western model of nephrology with the help of European Renal AssociationEuropean Dialysis and Transplant Association (ERA-EDTA) and International Society of Nephrology (ISN).
The introduction of erythropoiesis stimulating agents (ESAs) has changed the management of renal anemia, leading to substantial reduction in the blood transfusion requirements, improvement in energy and physical function and improvement in health-related quality of life. However introduction of ESAs had a long haul in Lithuania: we did not have epoetin until 1994 Renal Best Practice (ERBP) statements today, but, until then, hemoglobin (Hb) target range of 100-105 g/L was recommended. Maintaining Hb levels within such a narrow target range was a challenge in our clinical practice, so Hb variability was highly prevalent in our dialysis patients.
First data about control of renal anemia in HD patients in Lithuania were published in 2003 [1] . Authors presented relationship between lethality of HD patients and renal anemia control. They concluded that adequate HD procedures and a good management of HD patients decreased requirement of erythropoietin doses for renal anemia treatment. The aim of this study is (1) to analyse the changes of renal anemia control in HD patients depending on local protocols from early independence of Lithuania till nowadays; (2) to evaluate the link of anemia with hospitalization rate and survival; (3) to evaluate Hb variability in association with mortality.
Materials and Methods
In the absence of official Renal Registry in Lithuania, in December of each year starting from 1996, all HD centers of the country have been visited and data has been collected using special paper questionnaires. Information about the number of patients and HD stations, demographic characteristics, etiology of end stage renal disease (ESRD), data about dialysis quality, blood tests, and the medicines used have been obtained. Changes of renal anemia control in HD patients depending on local protocols were evaluated from early independence of Lithuania till nowadays. Influence of anemia on hospitalization rate was evaluated in a prospective study performed in 2002-2006. We investigated 559 patients from Kaunas region of Lithuania. The Kaunas region accounts for 12% of the Lithuanian territory and for 20% of the population. During the study 27% of all Lithuanian ESRD patients were hemodialysed in Kaunas region. Kaunas HD patients were representative of overall Lithuanian HD population: a comparative analysis using all Lithuanian data showed no statistically significant differences in age, gender, primary cause of ESRD, and hospitalization rate. Patients were followed prospectively 12 month for hospitalization rate, length of hospital stay, and causes of hospitalization.
Using data, collected at annual visits to HD centres, study on mortality of HD patients was performed. All patients who started chronic HD due to ESRD in Lithuania, between January 1, 1998 and December 31, 2005, were enrolled in our study. Outcomes and mortality and survival rates were analysed in the study.
Hb variability in HD patients was evaluated in another single-center, retrospective study ( = 100 Spearman's rank correlation coefficient was used to evaluate relationship between sets of data. The cumulative survival rate was estimated using the KaplanMeier method. The event of interest was death. Univariate Cox proportional hazards analysis was used to select variables significantly associated with the risk of death; then these variables were included in multivariate Cox proportional hazards models. Relative risk of hospitalization according to laboratory tests was estimated using Cox regression analysis model. Significant values were considered when < 0.05. (Table 1) . These changes were statistically significant during the first years of observation ( Table 1) . The target Hb level in patients on chronic HD was between 100 g/L and 105 g/L during the study according to our national algorithm for the management of anemia in Lithuania (it was introduced on 2000). The target of Hb is debated to this day. K/DOQI guidelines [2] and European Best Practice Guidelines [3] have recommended Hb target of 110 to 120 g/L and >110 g/L, respectively. 2012 KDIGO guidelines suggested limitation of the upper Hb level to ≤115 g/L [4] . So Hb 107 g/L was sufficient according to national and KDIGO guidelines in 2010, but it was too low as compared with other recommendations. According to results of The dialysis outcomes and practice patterns study (DOPPS), the same mean Hb of prevalent HD patients as in Lithuania was observed only in Japan (104 g/L in DOPPS III) [5] . Japanese Society for Dialysis Therapy recommended that a Hb level of 110-120 g/L at the first dialysis session in week is desirable in relatively young patients [6] . While it holds that the Hb level of the Japanese population seemed to be low when compared with that of the European and American populations, the mean Hb of other countries in DOPPS III was 115-120 g/L [5] . In 2010 76.6% of patients received epoetin in Lithuania. This percentage was low as compared to results of DOPPS study in 2010: lowest percentage was observed in Japan (87.3%) and Austria (87.7%) and ranged from 89.2% (France) till 96% (Belgium) in other countries [7] . In Lithuania 51.5% of HD patients was treated with epoetin beta, and 43.3% with epoetin alfa in 2005. Treatment with darbepoetin alfa was started in 2005 in Lithuania, so only 5.2% of patients received this medication. Increase of long-acting ESA usage was observed during 2005-2010. Percentage of patients treated with darbepoetin increased till 48.4% in 2010 in Lithuania as compared to 45.8% of patients in UK, 50.7% in Japan, and only 6.1% in USA [7] . Mircera is registered but not reimbursed in Lithuania so our HD patients have a possibility of this treatment only in frames of ongoing clinical trial. 25% of HD patients in France and 15.5% in Belgium were receiving Mircera in DOPPS study in 2010 [7] .
Results and Discussion
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The Role of Intravenous Iron (Experience of Lithuania).
The oral route of iron administration was popular in Lithuania before 1997. Our results coincided with the data of other studies confirming importance of the intravenous route of iron administration in CKD HD patients as compared to oral administration [8, 9] . Intravenous iron administration led to a greater increase in Hb concentration, a lower ESA dose, or both in most studies [4] . Limitations to the prescription of epoetin were introduced by Lithuanian Ministry of Health at the same time with unavailable intravenous iron. This was followed by worsening of the control of renal anemia in 2002. According to this new algorithm target Hb was 100-105 g/L for HD patients and maximum weekly dose of epoetin was 20000 IU. The mean Hb concentration decreased to 101 ± 14 g/L, the percentage of patients with Hb >100 g/L decreased to 51.8%, the percentage of HD patients receiving epoetin decreased to 88.8%, and the mean weekly dose of epoetin decreased to 7145 ± 3882 U, < 0.001 (Table 1 ). The rules (Table 2 ). All these changes were statistically significant. The changes of mean Hb due to influence of national algorithm and deficiency of iron are presented in Figure 1 . Insufficiency of iron increased between 2002 and 2004, and percentage of patients with ferritin <100 mcg/L decreased till 18.5% in 2005 ( < 0.001, Table 2 ). It is true to say that Lithuania had involuntary experiment to show influence of intravenous iron for the treatment of renal anemia. It is a pity that this experiment was very expensive as it lasted four years and all patients were involved.
Influence of Anemia on Hospitalization Rate in HD Patients from Kaunas Region of Lithuania.
There is no unified opinion about the influence of anemia to hospitalization rate of HD patients. Big retrospective study of dialysis patients showed that higher concentration of Hb associated with lower rate of hospitalization [10] . DOPPS study (data from 5 European countries) showed that higher Hb concentrations were associated with decreased relative risk of hospitalization: patients with Hb <100 g/L were 29% more likely to be hospitalized than patients with Hb 110-120 g/L [11] . But in prospective randomized trials hospitalization rate did not differ between groups of lower and higher Hb [12] . There were no Lithuanian data about relationship between hospitalization of HD patients and anemia till our study. Relative risk of hospitalization was estimated using Cox regression evaluating time to first hospitalization. Multivariate Cox regression model revealed that relative risk for hospitalization decreased by 0.98 for every 1 g/L rise of Hb (adjusted to age, sex, comorbid conditions, albumin, urea and phosphorus concentrations interdialytic weight gain, nonadherence to medications, systolic blood pressure before and dialysis, disability status). Cutoff value for Hb was <100 g/L: relative hospitalization risk increased by 1.7 (95% CI 1.4-1.95, < 0.001) in patients with Hb <100 g/L (Figure 2 ).
Association of Anemia with Mortality in HD Patients in Lithuania.
Annual data collection allows us to analyse associations between anemia and mortality in incident HD patients in Lithuania in 1998-2005. Analysis revealed that the mean Hb value of all these patients was 101.28 ± 12.59 g/L; in males it was higher than in females (102.34 ± 12.52 g/L versus 100.01 ± 12.56 g/L, < 0.001) and did not differ comparing different age groups and primary renal disease groups.
Multivariate Cox proportional hazards analysis revealed that anemia was an independent risk factor of death (RR = 0.952, 95% CI 0.945-0.959, < 0.001). Relative risk of mortality was 5% lower for every 1 g/L greater Hb concentration used as continuous variable and adjusted for age, sex, and primary kidney disease.
As shown in Table 3 of >106 g/L were not associated with a lower risk of death. For Hb concentrations ≥130 g/L, a trend towards higher mortality risk was observed (RR = 2.356, 95% CI 0.953-5.822, = 0.063), but it did not reach statistical significance. Anemia is associated with an increased risk of morbidity and mortality principally due to cardiac disease and stroke [13, 14] . Hb concentration <100 g/L is independent risk factor of cardiovascular diseases for dialysis patients [15] . DOPPS study showed that higher Hb concentrations were associated with decreased relative risk for mortality [11] . On the other hand, clinical trials showed that maintenance of Hb levels above 130 g/L may be associated with increased morbidity and mortality in dialysis. A recent meta-analysis indicated increased mortality at higher Hb target [12] . A trend towards a higher mortality risk was observed for patients with Hb concentrations >130 g/L in our study. [16] . There is conflicting evidence on the effect of Hb variability on mortality with some studies demonstrating a strong association and others showing no association with mortality. We evaluated Hb concentrations and ESA doses in 100 patients-56 (56%) men and 44 (44%) women. The mean age of patients was 61.88±14.8 years (31-84). Mean time from the start of dialysis until inclusion into the study was 4.75 ± 4.33 years. The new anemia management algorithm in Lithuania (August 2011) gave a clear rise in the Hb concentrations during the second half-year of 2011 (Figure 3) . We found that Hb concentrations increased significantly with a new algorithm, though mean doses of ESA remained unchanged (11073.17 U/week versus 11425 U/week; = 0.491).
Hemoglobin Variability in Lithuanian HD
We looked in detail to each month (01/2011-06/2011) Hb concentrations and found that only 17.1% of patients during this period had Hb in the target range according to local algorithm (100-105 g/L), 50.2% of patients had Hb <100 g/L, and 32.7% had Hb >105 g/L. A big part of our patients exhibited fluctuations in the Hb levels corresponding to literature data where we found that 80-90% of ESRD patients on dialysis exhibit fluctuations in the Hb levels, known as Hb variability [16] [17] [18] [19] . We used the six groups classification system (Ebben's principle) based on the lowest and the highest Hb categories seen during the 6-month observation period in our study and found: LL 10.9%; II 0%, HH 2.2%, LI 8.7%, IH 4.3%, and LH 73.9% of patients ( Figure 4 ). In the United States Renal Data System analysed by Ebben et al. [20] , only 10% of patients maintained Hb levels within a single Hb category during the entire 6-month period. 29% of patients experienced Hb fluctuations between the high and target Hb groups, and 21% experienced fluctuations between the low and target Hb groups. Fluctuation across all three Hb categories during the 6-month period was observed in nearly 40% of patients [20] . We noted that none of our ESA-treated patients had Hb levels stable within the target range (100-105 g/L) over a 6-month period; 10.9% of patients had constantly low Hb concentration; 13% strayed outside their initial Hb group into the next closest group, 73.9% of the patients showed a high amplitude swing. However it is difficult to compare our data with data of other studies because a different target range of Hb concentration was used; beside, there is no single and uniformly accepted method to measure Hb variability.
The data on the effect of Hb variability on mortality are conflicting. In our study we did not find the association between Hb variability and all-cause mortality using an adjusted Cox regression model, although the Hb concentrations of dead patients had a tendency to be lower ( Figure 5 ) and the mean ESA doses had a tendency to be higher.
The study of Ebben et al. suggested that variability itself may not have a strong association with mortality. The key factors seem to be the number and timing of Hb values <110 g/L. Patients whose Hb levels were consistently within the target range of 110 to 125 g/L experienced the lowest mortality in their study. The longer the amount of time with Hb level <110 g/L was the greater the risk of death was noted [19] . In a study involving 34 963 HD patients Yang and colleagues reported that the risk of all-cause mortality increased proportionately with Hb variability [21] . The HR and 95% CI per 0.5 g/dL, 0.75 g/dL, 1.00 g/dL, and 1.5 g/dL increases in Hb variability were 1.15 (1.10 to 1.2), 1.24 (1.16 to 1.32), 1.33 (1.22 to 1.45), and 1.53 (1.35 to 1.75), respectively. Not all studies have demonstrated a positive association between Hb variability and death in CKD. In the study of Eckardt and colleagues [17] Hb variability was not a statistically significant factor for mortality, except in the group of patients with low
